+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Europe Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity

  • ID: 5206694
  • Report
  • May 2021
  • Region: Europe
  • 140 Pages
  • GMD Research

FEATURED COMPANIES

  • AstraZeneca plc
  • Bavarian Nordic A/S
  • CSL Ltd.
  • Daiichi Sankyo Co. Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson
Europe preventive vaccines market accounted for $10.64 billion in 2020 and will grow by 10.72% annually over 2020-2026 owing to the increasing healthcare expenditure, new development of the vaccines, and rising need for preventive vaccines especially new COVID-19 vaccines.





Highlighted with 61 tables and 52 figures, this 140-page report “Europe Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity” is based on a holistic research of the entire Europe preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides estimate/forecast from 2020 till 2026 with 2019 as the base year.

In-depth qualitative analyses include identification and investigation of the following aspects:
  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Fiver Forces

The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Country.

Based on Vaccine Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
  • Live/Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • Toxoid Vaccines
  • Conjugate Vaccines
  • Recombinant Vector Vaccines
  • Other Vaccines

Based on Disease, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
  • Vaccines for Pneumococcal Disease
  • Vaccines for Poliovirus
  • Vaccines for Hepatitis
  • Vaccines for Influenza
  • Vaccines for Measles, Mumps, and Rubella (MMR)
  • Vaccines for Varicella
  • Vaccines for Human Papilloma Virus
  • Vaccines for COVID-19
  • Vaccines for Other Diseases

Based on Administration, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
  • Intramuscular Route
  • Subcutaneous Route
  • Oral Route
  • Intravenous Injection
  • Other Administration Routes

Based on Patient, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
  • Pediatric Vaccines
  • Pneumococcal
  • Measles, Mumps, and Rubella (MMR)
  • Varicella
  • Hepatitis
  • Poliovirus
  • Haemophilus Influenzae B (HIB)
  • Other Diseases
  • Adult Vaccines
  • Influenza
  • Cervical Cancer
  • Hepatitis
  • Zoster
  • Other Diseases

Geographically, the following national/local markets are fully investigated:
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)

For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Europe preventive vaccines market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • China National Biotec Group Company Ltd.
  • CSL Ltd.
  • Daiichi Sankyo Co. Ltd
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co.
  • Moderna Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Frequently Asked Questions about the European Preventive Vaccines Market

What is the estimated value of the European Preventive Vaccines Market?

The European Preventive Vaccines Market was estimated to be valued at $10637.3 Million in 2020.

What is the growth rate of the European Preventive Vaccines Market?

The growth rate of the European Preventive Vaccines Market is 10.7%, with an estimated value of $19595.3 Million by 2026.

What is the forecasted size of the European Preventive Vaccines Market?

The European Preventive Vaccines Market is estimated to be worth $19595.3 Million by 2026.

Who are the key companies in the European Preventive Vaccines Market?

Key companies in the European Preventive Vaccines Market include AstraZeneca plc, Bavarian Nordic A/S, China National Biotec Group Company Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd, Emergent BioSolutions Inc., GlaxoSmithKline plc, Johnson & Johnson and Moderna Inc..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca plc
  • Bavarian Nordic A/S
  • CSL Ltd.
  • Daiichi Sankyo Co. Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson

1 Introduction
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Five Forces Analysis
3 Segmentation of Europe Market by Vaccine Type
3.1 Market Overview by Vaccine Type
3.2 Live/Attenuated Vaccines
3.3 Inactivated Vaccines
3.4 Subunit Vaccines
3.5 Toxoid Vaccines
3.6 Conjugate Vaccines
3.7 Recombinant Vector Vaccines
3.8 Other Vaccines
4 Segmentation of Europe Market by Disease
4.1 Market Overview by Disease
4.2 Vaccines for Pneumococcal Disease
4.3 Vaccines for Poliovirus
4.4 Vaccines for Hepatitis
4.5 Vaccines for Influenza
4.6 Vaccines for Measles, Mumps, and Rubella (MMR)
4.7 Vaccines for Varicella
4.8 Vaccines for Human Papilloma Virus
4.9 Vaccines for COVID-19
4.10 Vaccines for Other Diseases
5 Segmentation of Europe Market by Administration
5.1 Market Overview by Administration
5.2 Intramuscular Route
5.3 Subcutaneous Route
5.4 Oral Route
5.5 Intravenous Injection
5.6 Other Administration Routes
6 Segmentation of Europe Market by Patient
6.1 Market Overview by Patient
6.2 Pediatric Vaccines
6.3 Adult Vaccines
7 European Market 2020-2026 by Country
7.1 Overview of European Market
7.2 UK
7.3 France
7.4 Germany
7.5 Spain
7.6 Italy
7.7 Russia
7.8 Rest of European Market
8 Competitive Landscape
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • China National Biotec Group Company Ltd.
  • CSL Ltd.
  • Daiichi Sankyo Co. Ltd
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co.
  • Moderna Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.

9 Investing in Europe Market: Risk Assessment and Management
9.1 Risk Evaluation of Europe Market
9.2 Critical Success Factors (CSFs)
List of Tables
Table 1. Snapshot of Europe Preventive Vaccines Market in Balanced Perspective, 2020-2026
Table 2. Growth Rate of World GDP, 2020-2022
Table 3. Main Product Trends and Market Opportunities in Europe Preventive Vaccines Market
Table 4. Europe Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn
Table 5. Europe Preventive Vaccines Market by Disease, 2016-2026, $ mn
Table 6. COVID-19 Vaccines Authorized for Emergency Use or Approved for Full Use, as of April 2021
Table 7. Europe Preventive Vaccines Market by Administration, 2016-2026, $ mn
Table 8. Europe Preventive Vaccines Market by Patient, 2016-2026, $ mn
Table 9. Europe Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn
Table 10. Europe Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn
Table 11. Europe Preventive Vaccines Market by Country, 2016-2026, $ mn
Table 12. UK Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn
Table 13. UK Preventive Vaccines Market by Disease, 2016-2026, $ mn
Table 14. UK Preventive Vaccines Market by Administration, 2016-2026, $ mn
Table 15. France Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn
Table 16. France Preventive Vaccines Market by Disease, 2016-2026, $ mn
Table 17. France Preventive Vaccines Market by Administration, 2016-2026, $ mn
Table 18. Germany Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn
Table 19. Germany Preventive Vaccines Market by Disease, 2016-2026, $ mn
Table 20. Germany Preventive Vaccines Market by Administration, 2016-2026, $ mn
Table 21. Spain Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn
Table 22. Spain Preventive Vaccines Market by Disease, 2016-2026, $ mn
Table 23. Spain Preventive Vaccines Market by Administration, 2016-2026, $ mn
Table 24. Italy Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn
Table 25. Italy Preventive Vaccines Market by Disease, 2016-2026, $ mn
Table 26. Italy Preventive Vaccines Market by Administration, 2016-2026, $ mn
Table 27. Russia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn
Table 28. Germany Preventive Vaccines Market by Disease, 2016-2026, $ mn
Table 29. Germany Preventive Vaccines Market by Administration, 2016-2026, $ mn
Table 30. Preventive Vaccines Market in Rest of Europe by Country, 2016-2026, $ mn
Table 31. AstraZeneca plc: Company Snapshot
Table 32. AstraZeneca plc: Revenue, 2018-2020, $ bn
Table 33. Bavarian Nordic A/S: Company Snapshot
Table 34. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020
Table 35. China National Biotec Group Company Ltd.: Company Snapshot
Table 36. CSL Ltd.: Company Snapshot
Table 37. Daiichi Sankyo Co. Ltd.: Company Snapshot
Table 38. Emergent BioSolutions Inc.: Company Snapshot
Table 39. GlaxoSmithKline: Company Snapshot
Table 40. GlaxoSmithKline: Business Segmentation
Table 41. GlaxoSmithKline: Product Portfolio
Table 42. GlaxoSmithKline: Revenue, 2018-2020, $ bn
Table 43. GlaxoSmithKline: Recent Developments
Table 44. Johnson & Johnson: Company Snapshot
Table 45. Johnson & Johnson: Business Segments
Table 46. Merck & Co., Inc.: Company Snapshot
Table 47. Merck & Co., Inc.: Business Segmentation
Table 48. Merck & Co., Inc.: Revenue, 2018-2020, $ bn
Table 49. Moderna Inc.: Company Snapshot
Table 50. Novavax, Inc.: Company Snapshot
Table 51. Pfizer Inc.: Company Snapshot
Table 52. Pfizer Inc.: Business Segmentation
Table 53. Pfizer Inc.: Product Portfolio
Table 54. Pfizer Inc.: Revenue, 2018-2020, $ bn
Table 55. Pfizer Inc.: Recent Developments
Table 56. Sanofi: Company Snapshot
Table 57. Sanofi: Business Segmentation
Table 58. Sanofi: Revenue, 2018-2020, $ bn
Table 59. Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 60. Risk Evaluation for Investing in Europe Market, 2020-2026
Table 61. Critical Success Factors and Key Takeaways
List of Figures
Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2026
Figure 4. Europe Preventive Vaccines Market, 2016-2026, $ mn
Figure 5. Development Stages of Preventive Vaccines
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Europe Preventive Vaccines Market
Figure 8. Primary Restraints and Impact Factors of Europe Preventive Vaccines Market
Figure 9. Investment Opportunity Analysis
Figure 10. Porter’s Five Forces Analysis of Europe Preventive Vaccines Market
Figure 11. Breakdown of Europe Preventive Vaccines Market by Vaccine Type, 2020-2026, % of Revenue
Figure 12. Contribution to Europe 2021-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%)
Figure 13. Europe Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn
Figure 14. Europe Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn
Figure 15. Europe Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn
Figure 16. Europe Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn
Figure 17. Europe Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn
Figure 18. Europe Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn
Figure 19. Europe Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn
Figure 20. Breakdown of Europe Preventive Vaccines Market by Disease, 2020-2026, % of Revenue
Figure 21. Contribution to Europe 2021-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%)
Figure 22. Europe Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn
Figure 23. Europe Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn
Figure 24. Europe Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn
Figure 25. Europe Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn
Figure 26. Europe Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn
Figure 27. Europe Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn
Figure 28. Europe Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn
Figure 29. Europe Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn
Figure 30. Europe Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn
Figure 31. Breakdown of Europe Preventive Vaccines Market by Administration, 2020-2026, % of Revenue
Figure 32. Contribution to Europe 2021-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%)
Figure 33. Europe Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn
Figure 34. Europe Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn
Figure 35. Europe Preventive Vaccines Market: Oral Route, 2016-2026, $ mn
Figure 36. Europe Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn
Figure 37. Europe Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn
Figure 38. Breakdown of Europe Preventive Vaccines Market by Patient, 2020-2026, % of Revenue
Figure 39. Contribution to Europe 2021-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%)
Figure 40. Europe Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn
Figure 41. Europe Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn
Figure 42. Breakdown of European Preventive Vaccines Market by Country, 2020 and 2026, % of Revenue
Figure 43. Contribution to Europe 2021-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 44. Preventive Vaccines Market in UK, 2016-2026, $ mn
Figure 45. Preventive Vaccines Market in France, 2016-2026, $ mn
Figure 46. Preventive Vaccines Market in Germany, 2016-2026, $ mn
Figure 47. Preventive Vaccines Market in Spain, 2016-2026, $ mn
Figure 48. Preventive Vaccines Market in Italy, 2016-2026, $ mn
Figure 49. Preventive Vaccines Market in Russia, 2016-2026, $ mn
Figure 50. Preventive Vaccines Market in Rest of Europe, 2016-2026, $ mn
Figure 51. Growth Stage of Europe Preventive Vaccines Industry over the Forecast Period
Figure 52. Top Products of AstraZeneca Based on Revenue from 2016 to 2019 (in million U.S. dollars)
Note: Product cover images may vary from those shown
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • China National Biotec Group Company Ltd.
  • CSL Ltd.
  • Daiichi Sankyo Co. Ltd
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co.
  • Moderna Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...